Spinosad - Generic Drug Details

What are the generic sources for spinosad and what is the scope of patent protection?

Spinosad is the generic ingredient in one branded drug marketed by Cipher and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for spinosad. Two suppliers are listed for this compound.

Summary for spinosad

US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	7,334
Drug Prices:	Drug price trends for spinosad
What excipients (inactive ingredients) are in spinosad?	spinosad excipients list
DailyMed Link:	spinosad at DailyMed

See drug prices for spinosad

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for spinosad

Constraining patent/regulatory exclusivity:

9,895,388

Dosage:

SUSPENSION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for spinosad

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Inotiv Laboratories	Phase 4
MicroConstants, Inc.	Phase 4
Concentrics Research	Phase 4

See all spinosad clinical trials

Pharmacology for spinosad

Drug Class

Pediculicide

US Patents and Regulatory Information for spinosad

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011		RX	Yes	Yes	9,895,388

Expired US Patents for spinosad

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011	5,496,931
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011	7,030,095
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011	6,063,771
Cipher	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011	6,342,482

EU/EMA Drug Approvals for spinosad

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Elanco GmbH	Comfortis	spinosad	EMEA/V/C/002233 Treatment and prevention of flea infestations (Ctenocephalides felis).The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).	Withdrawn	no	no	no	2011-02-11

Spinosad Market Dynamics and Financial Trajectory

Introduction to Spinosad

Spinosad is a natural biopesticide derived from the bacterium Saccharopolyspora spinosa. It has become a crucial component in sustainable agricultural practices and pest control due to its eco-friendly nature and effective pest management capabilities.

Market Size and Growth

The global Spinosad market is anticipated to experience significant growth in the coming years. As of 2024, the market size is estimated to be around USD 751.2 million to USD 814.41 million, depending on the source[1][4].

• By 2032, the market is projected to reach approximately USD 1.45 billion, exhibiting a robust Compound Annual Growth Rate (CAGR) of 7.52% to 8.00% during the forecast period[1][4].

Drivers of Market Growth

Several factors are driving the growth of the Spinosad market:

Increasing Demand for Organic Food

The global demand for organic and pesticide-free produce is on the rise. Consumers are becoming more health-conscious and aware of the environmental impact of synthetic pesticides, leading to an increased adoption of Spinosad in agricultural practices[1].

Favorable Government Regulations

Government policies and regulations supporting the use of biopesticides are a significant driver. In regions like North America and Europe, stringent regulations on synthetic pesticides have created a favorable environment for the adoption of Spinosad[1].

Integration into IPM Frameworks

Spinosad's broad-spectrum pest control capabilities and safety for non-target species make it an ideal solution for Integrated Pest Management (IPM) frameworks. This integration further boosts its market growth[1].

Climate Change and Pest Infestations

Rising pest infestations due to climate change have highlighted the need for effective and sustainable pest control solutions, contributing to the growing demand for Spinosad[1].

Market Trends

Several trends are shaping the Spinosad market:

Organic Farming Practices

The increasing integration of Spinosad in organic farming practices is a prominent trend. This is particularly evident in developed markets where regulatory frameworks support biopesticide use and organic food consumption is growing exponentially[1].

Residential Pest Control

Spinosad is also gaining traction in residential pest control and urban pest management due to its effectiveness against common household pests and low toxicity to humans and pets[1].

Regional Outlook

The Spinosad market has a varied regional landscape:

North America

North America is a dominant market for Spinosad, driven by the demand for organic produce and favorable government policies. The region is expected to grow at a CAGR of 6.2% from 2024 to 2031[4].

Europe

Europe also holds a significant market share, with a CAGR of 6.5% from 2024 to 2031. The region's stringent regulations on synthetic pesticides and growing demand for organic food contribute to this growth[4].

Asia-Pacific

The Asia-Pacific region is rapidly adopting Spinosad-based solutions, driven by expanding agricultural economies and the need for effective pest management. This region is expected to grow at a CAGR of 10% from 2024 to 2031[4].

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are also expected to witness steady growth, with CAGRs of 7.4% and 7.7%, respectively, from 2024 to 2031[4].

Market Opportunities

The Spinosad market presents several opportunities for growth:

Expanding Applications

Investments in R&D to develop cost-effective production methods and explore new pest control applications can unlock additional growth potential. This includes its adoption in non-agricultural sectors such as public health pest control and pet care[1].

Emerging Markets

Growing demand for organic produce in regions like Asia-Pacific and Latin America presents a lucrative market for Spinosad. Collaborations between governments and agricultural companies to promote sustainable farming practices can further enhance market penetration[1].

Financial Performance and Projections

The financial trajectory of the Spinosad market is robust:

• Revenue Growth: The market is expected to grow from USD 751.2 million in 2024 to USD 1.45 billion by 2032, indicating a significant increase in revenue over the forecast period[1][4].

• Regional Revenue: North America holds the largest market share, with USD 300.48 million in 2024, followed by Europe with USD 225.36 million, and the Asia-Pacific region with USD 172.78 million[4].

• CAGR: The global market is projected to grow at a CAGR of 7.52% to 8.00% from 2024 to 2032, reflecting a strong growth trajectory[1][4].

Challenges and Restraints

Despite the positive outlook, the Spinosad market faces some challenges:

• Supply Chain Disruptions: The COVID-19 pandemic highlighted the vulnerability of global supply chains, which can impact the production and distribution of Spinosad[4].

• Economic Uncertainties: Economic fluctuations can affect the demand and pricing of Spinosad, particularly in regions with less stable economic conditions[4].

Key Takeaways

• The Spinosad market is driven by increasing demand for organic food, favorable government regulations, and integration into IPM frameworks.
• The market is expected to grow significantly, with a CAGR of 7.52% to 8.00% from 2024 to 2032.
• North America and Europe are the dominant markets, but the Asia-Pacific region is growing rapidly.
• Emerging markets and expanding applications offer significant opportunities for growth.
• Despite challenges such as supply chain disruptions and economic uncertainties, the market is poised for robust growth.

FAQs

What is Spinosad and where is it derived from?

Spinosad is a natural biopesticide derived from the bacterium Saccharopolyspora spinosa. It is used for effective and sustainable pest control in various industries, including agriculture and residential pest management.

What are the key drivers of the Spinosad market growth?

The key drivers include increasing demand for organic food, favorable government regulations supporting biopesticides, integration into IPM frameworks, and rising pest infestations due to climate change.

Which regions are the dominant markets for Spinosad?

North America and Europe are the dominant markets for Spinosad, driven by stringent regulations on synthetic pesticides and growing demand for organic produce.

What are the potential opportunities for the Spinosad market?

Opportunities include expanding applications in non-agricultural sectors, growing demand in emerging markets like Asia-Pacific and Latin America, and investments in R&D for cost-effective production methods.

How has the COVID-19 pandemic impacted the Spinosad market?

The COVID-19 pandemic disrupted global supply chains and agricultural activities, affecting the production and distribution of Spinosad. However, it also heightened awareness of food security and sustainability, spurring renewed interest in natural pest control methods like Spinosad.

What is the projected CAGR for the Spinosad market from 2024 to 2032?

The global Spinosad market is projected to grow at a CAGR of 7.52% to 8.00% from 2024 to 2032.

Sources

1. Global Growth Insights: Spinosad Market Share & Trends [2024-2032][1]
2. Biospace: Cipher Pharmaceuticals Reports Third Quarter 2024 Results (Note: This source is not directly related to Spinosad but provides context on pharmaceutical market dynamics)[2]
3. Cipher Pharmaceuticals: Second Quarter 2024 Results (Note: This source is not directly related to Spinosad but provides context on pharmaceutical market dynamics)[3]
4. Cognitive Market Research: Spinosad Market Report[4]